48,830
edits
(→Techniques: more) |
|||
Line 61: | Line 61: | ||
*[[Immunohistochemical stains]]. | *[[Immunohistochemical stains]]. | ||
**[[Cancers of unknown primary]]. | **[[Cancers of unknown primary]]. | ||
*Targeted therapies | *Targeted therapies/molecular testing: | ||
**Receptors in breast cancer. | **Receptors in breast cancer (ER, PR, HER2). | ||
**Lung cancer biomarkers ([[Lung_carcinoma_with_EGFR_mutation|EGFR]], [[Lung carcinoma with ALK rearrangement|ALK]], PD-L1, [[ROS1-rearranged non-small cell lung carcinoma|ROS1]]). | |||
**BRAF testing in malignant melanoma. | |||
**[[Microsatellite instability in colorectal cancer|MSI testing]] in colorectal cancer. | |||
==See also== | ==See also== |
edits